5-((1-(6-(trifluoromethyl)-1H-benzo(d)imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyrdin-2(1H)-one,
BGB-283,
lifirafenib,
UNII-8762XZS5ZF,
8762XZS5ZF,
BGB-283,
BGB283,
1446090-77-2,
Beigene-283,
5-({(1r,1as,6br)-1-[5-(Trifluoromethyl)-1h-Benzimidazol-2-Yl]-1a,6b-Dihydro-1h-Cyclopropa[b][1]benzofuran-5-Yl}oxy)-3,4-Dihydro-1,8-Naphthyridin-2(1h)-One,
5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one,
compound 2.2b,
1446090-79-4,
Lifirafenib [USAN],
GTPL8958,
SCHEMBL15085288,
EX-A1473,
MFCD30502667,
WHO 10554,
ZINC68764621,
AKOS030527927,
CS-6308,
HY-18957,
1,8-Naphthyridin-2(1H)-one, 5-(((1R,1aS,6bR)-1a,6b-dihydro-1-(6-(trifluoromethyl)-1H-benzimidazol-2-yl)-1H-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-,
3K3,
5-(((1R,1aS,6bR)-1-(6-(Trifluoromethyl)-1H-benzimidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa(b)benzofuran-5-yl)oxy)-3,4-dihydro-1H-1,8-naphthyridin-2-one,
5-(((1S,1aR,6bS)-1-(6-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one,
5-[[(1R,1aS,6bR)-1-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]-1a,6b-dihydro-1H-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one,